Key indicators:

• Turnover up 15% compared to H1 2024
• EBITDA increased by 14%, reaching RON 61.7 million
• Net profit of RON 48.8 million, up approximately 16%
• Biofarm ranks second in the Consumer Healthcare (CHC) segment by number of units sold
• The company is the market leader by volume in the reference categories for six brands: Bixtonim, Colebil, Triferment, Extravalerianic, Carmol, and Carbocit

Bucharest, 18 August, 2025 – Biofarm (stock symbol BIO), one of the largest pharmaceutical manufacturers in Romania, closed the first half of 2025 with solid performance, confirming the growth pace targeted by the company. Turnover increased by 15% compared to the first half of 2024, EBITDA rose by 14% to RON 61.7 million, and net profit reached RON 48.8 million, up approximately 16%.

 „In an economic context marked by exchange rate volatility, rising raw material costs, and legislative changes such as the VAT rate adjustment, we remain committed to research and development, a key pillar of our sustainable growth strategy. We continue to invest in portfolio innovation and in identifying therapeutic solutions adapted to the new market realities and consumer needs,” said Cătălin Vicol, CEO of Biofarm.

In the first six months of 2025, Biofarm consolidated its second place in the Consumer Healthcare (CHC) segment by number of units sold. Sales growth was supported by significant increases in brands dedicated to digestive health, pain management, symptomatic treatment of cold and flu, as well as products addressing stress and anxiety. 
 
The company is the market leader by volume in the reference categories for six of its brands: Bixtonim, Colebil, Triferment, Extravalerianic, Carmol, and Carbocit. 
 
Biofarm operates two pharmaceutical factories in Bucharest and a product testing and development facility. Its portfolio of over 100 products covers the most important therapeutic areas in the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system). Continuous innovation in product development remains one of the fundamental drivers of Biofarm’s expansion and the consolidation of its position among the leaders in the pharmaceutical industry.   

 

About Biofarm 

Biofarm® is one of the first Romanian drug and food supplements producers. For 100 years, Biofarm® has stood alongside Romanian specialists in the race to discover the best solutions for maintaining people's health. Biofarm® is currently one of the top 10 existing producers on the pharmaceutical market in Romania, a very dynamic and competitive market. Biofarm® has a competitive product portfolio, covering 65 therapeutic areas, and is continuously investing in media, commercial and marketing campaigns to promote its products.